← board
EOLS
distress 2/10 · well-funded / low risk$5.98+2%today-38% from 52w high
Lead: aesthetic
Revenue
$73M
Liquidity
$50M
Runway
1.4 yrs
Shares 1y
+2%
Price & events
+17.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.5%
1D
+6.2%
1W
-11.3%
1M
+12.6%
3M
+21.5%
6M
-37.6%
1Y
-52.5%
2Y
-45.1%
5Y
+86.9%
All
Overview
- Market Cap
- $393.81M
- Enterprise Value
- $500.43M
- Volume
- 78.17K
- 52 Week Range
- $3.94 – $9.65
- Total Shares
- 65.85M
- Float Shares
- 50.04M
- Short %
- 9.25%
- % Held by Insiders
- 14.68%
- % Held by Institutions
- 70.35%
- RVOL
- 0.10x
- Beta
- 1.32
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- Q4 2026Guided 70%PDUFAPDUFAEvolysse Sculpt · anticipates U.S. approvalSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-05-05partnershipEntered into amended and restated credit facility with Pharmakon for up to $250 millionSEC 8-K
Approved drugs (1)
- JEUVEAUPRABOTULINUMTOXINA-XVFS2019 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+145% upside) · 6 analysts
- 2026-06-17BTIGBuy
- 2026-03-04BTIGBuy
- 2026-02-03HC Wainwright & Co.Buy
- 2026-01-22BTIGBuy
- 2026-01-13StifelBuy
- 2026-01-09HC Wainwright & Co.Buy
Competitors — aesthetic
- none identified
Recent news
- 2026-07-22Evolus to Report Second Quarter Financial Results on August 5, 2026 - Yahoo Finance
- 2026-07-19Evolus, Inc. (EOLS) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-18(EOLS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
- 2026-07-18Evolus, Inc. (EVL) Q3 2025 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-18Evolus, Inc. (EVL) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-18Evolus, Inc. (EVL) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-15Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com - Investing.com Nigeria
- 2026-07-10Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.